Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Harinder Gill, Chul Won Choi, Hein Than, Hsin-An Hou, Chul Won Jung, Yok-Lam Kwong, Garret M. K. Leung, Melissa G. M. Ooi, Ponlapat Rojnuckarin, David M. Ross, Lee-Yung Shih, Katsuto Takenaka, Winnie Z. Y. Teo, Keita Kirito

Blood (2024) 144 (Supplement 1): 3678.

https://doi.org/10.1182/blood-2024-201402

Published: 2024

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Blood (2022) 140 (Supplement 1): 1018–1019.

https://doi.org/10.1182/blood-2022-166182

Published: 2022

Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Blood (2022) 140 (Supplement 1): 6592–6593.

https://doi.org/10.1182/blood-2022-171149

Published: 2022

Journal Articles

First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Chul Won Jung, Sung-Soo Yoon, Martha L. Arellano, Jiyeon Yoon, Nora Lee, Hyunjin Kim, Jaeyeon Lee, Brian A. Jonas, Seungjae Baek

Blood (2021) 138 (Supplement 1): 702.

https://doi.org/10.1182/blood-2021-150014

Published: 2021

Journal Articles

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

Naval Daver, MD, Kyoo Hyung Lee, MD PhD, Chul Won Jung, MD PhD, Yoon Sung Soo, MD PhD, Martha L. Arellano, MD, Brian A Jonas, MD PhD, Jiyeon Yoon, PhD, Sooa Jung, PhD, Young Su Noh, PhD, Inhwan Bae, PhD, Song Kim, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143244

Published: 2020

Journal Articles

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Naval G. Daver, MD, Kyoo Hyung Lee, MD PhD, Sung-Soo Yoon, MD PhD, Chul Won Jung, MD PhD, Hyun Jeong Kang, Sooa Jung, Sujin Seo, Jiyeon Yoon, Hyunjin Kim, Young Su Noh, Yoonha Seo, Hyeyoung Kwon, Oakpil Han, Seungjae Baek, MD PhD, Kyounghee Seo, Kwee Hyun Suh, PhD

Blood (2019) 134 (Supplement_1): 1331.

https://doi.org/10.1182/blood-2019-129670

Published: 2019

Journal Articles

Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study

Joon Young Hur, MD, Kang Kook Lee, MD, Jun Ho Jang, MD PhD, Kihyun Kim, MD PhD, Chul Won Jung, MD PhD, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2018-99-114858

Published: 2018

Journal Articles

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Joon Young Hur, MD, Kang Kook Lee, MD, Sang Eun Yoon, MD, Sehhoon Park, MD, Jangho Cho, MD, Youjin Kim, MD, Eunseok Jeon, MD PhD, Jinoh Choi, MD PhD, Gayeon Lee, MD PhD, Byungjun Kim, MD PhD, Ju Hong Min, MD PhD, Jung Sun Kim, MD PhD, Jung Eun Lee, MD PhD, Joon Young Choi, MD PhD, Seok Jin Kim, MD PhD, Jun Ho Jang, MD PhD, Won-Seog Kim, MD PhD, Chul Won Jung, MD PhD, Kihyun Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3256.

https://doi.org/10.1182/blood-2018-99-114099

Published: 2018

Journal Articles

Hematologic Response to Romiplostim Treatment Is Associated with Stimulation of Primitive Stem/Progenitor Cells and Stromal Cells in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: A 2-Year Interim Exploratory Analysis of a Phase 2 Clinical Trial

Jong-Wook Lee, MD, Sung-Eun Lee, MD, Chul Won Jung, Silvia Park, Jin-A Kim, Il-Hoan Oh, MD PhD, Jun Ho Jang, MD PhD

Blood (2017) 130 (Supplement 1): 1167.

https://doi.org/10.1182/blood.V130.Suppl_1.1167.1167

Published: 2017

Journal Articles

Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

Blood (2017) 130 (Supplement 1): 3114.

https://doi.org/10.1182/blood.V130.Suppl_1.3114.3114

Published: 2017

Journal Articles

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Blood (2017) 130 (Supplement 1): 5075.

https://doi.org/10.1182/blood.V130.Suppl_1.5075.5075

Published: 2017

Journal Articles

Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype

Blood (2016) 128 (22): 2876.

https://doi.org/10.1182/blood.V128.22.2876.2876

Published: 2016

Journal Articles

Genome-Wide Genotype-Based Risk Model for Survival in Core Binding Factor Acute Myeloid Leukemia Patients

Silvia Park, Choi Hangseok, Hee-Je Kim, Jae-Sook Ahn, Hyeoung Joon Kim, MD PhD, Sung-Hyun Kim, Yeung-Chul Mun, Chul Won Jung, MD PhD, Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 1623.

https://doi.org/10.1182/blood.V128.22.1623.1623

Published: 2016

Journal Articles

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Blood (2016) 128 (22): 5253.

https://doi.org/10.1182/blood.V128.22.5253.5253

Published: 2016

Journal Articles

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Soo-Mee Bang, Yeung-Chul Mun, Ho-Jin Shin, MD PhD, Chul Won Jung, Sung Hwa Bae, Sang Kyun Sohn, Kyoung Ha Kim, Hawk Kim, Ho-Young Yhim, MD PhD, Junshik Hong, Hye Joo Kim, Jae-hoon Lee, Doyeun Oh

Blood (2016) 128 (22): 4938.

https://doi.org/10.1182/blood.V128.22.4938.4938

Published: 2016

Journal Articles

Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression

Blood (2016) 128 (22): 52.

https://doi.org/10.1182/blood.V128.22.52.52

Published: 2016

Journal Articles

Measurement of Quality of Life and Depression of Spouse Caregivers for Survivors after Hematopoietic Stem Cell Transplantation

Silvia Park, Juhee Cho, Jun Ho Jang, Chul Won Jung, Mi Hwa Heo

Blood (2016) 128 (22): 4775.

https://doi.org/10.1182/blood.V128.22.4775.4775

Published: 2016

Journal Articles

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Yoo Jin Lee, MD, Joon Ho Moon, MD, PhD, In Hee Lee, MD, Jae-Ho Yoon, Byung-Sik Cho, Jae-Sook Ahn, MD PhD, Hyeoung Joon Kim, MD PhD, Silvia Park, Jun Ho Jang, MD PhD, Chul Won Jung, MD PhD, Hyunsung Park, MD, June-Won Cheong, MD, Je-Hwan Lee, MD PhD, Sang Kyun Sohn, MD, PhD, Hee-Je Kim

Blood (2016) 128 (22): 4566.

https://doi.org/10.1182/blood.V128.22.4566.4566

Published: 2016

NARROW

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Hematologic Response to Romiplostim Treatment Is Associated with Stimulation of Primitive Stem/Progenitor Cells and Stromal Cells in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: A 2-Year Interim Exploratory Analysis of a Phase 2 Clinical Trial

Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype

Genome-Wide Genotype-Based Risk Model for Survival in Core Binding Factor Acute Myeloid Leukemia Patients

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression

Measurement of Quality of Life and Depression of Spouse Caregivers for Survivors after Hematopoietic Stem Cell Transplantation

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only